Janney Capital Management LLC Buys 1,564 Shares of Johnson & Johnson (NYSE:JNJ)

Janney Capital Management LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 166,099 shares of the company’s stock after purchasing an additional 1,564 shares during the period. Johnson & Johnson makes up 2.2% of Janney Capital Management LLC’s investment portfolio, making the stock its 3rd biggest holding. Janney Capital Management LLC’s holdings in Johnson & Johnson were worth $27,134,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Janney Montgomery Scott LLC increased its position in shares of Johnson & Johnson by 2.1% during the third quarter. Janney Montgomery Scott LLC now owns 1,225,081 shares of the company’s stock worth $200,129,000 after acquiring an additional 24,630 shares in the last quarter. Guyasuta Investment Advisors Inc. increased its position in shares of Johnson & Johnson by 0.8% during the third quarter. Guyasuta Investment Advisors Inc. now owns 263,385 shares of the company’s stock worth $43,027,000 after acquiring an additional 2,085 shares in the last quarter. Matrix Trust Co increased its position in shares of Johnson & Johnson by 42.8% during the third quarter. Matrix Trust Co now owns 6,314 shares of the company’s stock worth $1,031,000 after acquiring an additional 1,892 shares in the last quarter. Renaissance Investment Group LLC increased its position in shares of Johnson & Johnson by 1.6% during the third quarter. Renaissance Investment Group LLC now owns 9,361 shares of the company’s stock worth $1,601,000 after acquiring an additional 150 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in shares of Johnson & Johnson by 0.9% during the third quarter. Fifth Third Bancorp now owns 1,452,743 shares of the company’s stock worth $237,321,000 after acquiring an additional 13,212 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Bank of America reduced their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Citigroup upped their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Sanford C. Bernstein reduced their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. Finally, Raymond James dropped their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $182.42.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Peter Fasolo sold 22,864 shares of the stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold 300,750 shares of company stock worth $52,311,677 in the last three months. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $174.88 on Thursday. The stock has a market capitalization of $457.22 billion, a P/E ratio of 24.36, a PEG ratio of 3.45 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The firm’s 50 day moving average is $176.22 and its 200 day moving average is $171.59. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The company had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.60 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.58%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson declared that its Board of Directors has approved a share buyback program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.